Stefan Borgwardt

Chair of Psychiatry and Psychotherapy at the University of Lübeck

Data updated

Papers

23 publications

Trials

0 clinical trials

Research Footprint

Stefan Borgwardt appears in 23 tracked papers (2015–2026), most studied alongside LSD, MDMA and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Anxiety Disorders.

Most-cited paper: Acute effects of lysergic acid diethylamide in healthy subjects (424 citations).

Frequent co-authors: Matthias Liechti, Felix Müller and Lukas Ley.

Background & Research

Stefan Borgwardt is a prominent German psychiatrist whose research utilizes structural and functional neuroimaging to understand the effects of psychoactive drugs on the brain. His team explores the early phases of psychosis and evaluates the efficacy of cannabinoids and psychedelics in treating major depression and schizophrenia, integrating genetic and computational modeling into clinical care.

Key Impact

Researches neurofunctional mechanisms of innovative treatments like cannabinoids and psychedelics for psychosis and depression.

23

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

21 collaborators· click a node to visit their profile

Full network →

Compounds

LSDMDMAPlaceboPsilocybin

Topics

Healthy VolunteersNeuroimaging & Brain MeasuresAnxiety DisordersDepressive DisordersMedicinal Chemistry & Drug DevelopmentSchizophreniaInterpersonal Functioning & Social ConnectednessSubstance Use Disorders (SUD)Neurocognitive DisordersPTSDPalliative & End-of-Life DistressPersonality & Trait FactorsBipolar DisorderMajor Depressive Disorder (MDD)Safety & Risk ManagementPublic Health, Prevention & Behaviour ChangeTreatment-Resistant Depression (TRD)SuicidalityPersonality Disorders

Top Collaborators

Affiliations

Institutions, companies, and organisations Stefan Borgwardt is associated with.

King's College London

academic

The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.

View stakeholder →

University of Basel

academic

The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.

View stakeholder →